Compounding Pharmacies Diabetes Documentation 
STAT
OCTOBER 22, 2024
Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make. The FDA still has to make a decision on whether to officially place semaglutide on the lists.
STAT
OCTOBER 23, 2024
Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make , STAT reports. … Novo Nordisk has asked the U.S.
STAT
DECEMBER 4, 2024
It mirrors results seen in the companies’ diabetes drugs, which use the same active ingredients. But documenting the differences between Zepbound and Wegovy in a rigorous way might allow Lilly to make marketing claims about Zepbound’s superior efficacy. That, in turn, could help the company gain market share against Novo.
Expert insights. Personalized for you.
362 
Let's personalize your content